Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
ADVERTISEMENT Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth.
Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income.
For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution.
We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25.
ADVERTISEMENT We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend.
ADVERTISEMENT Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude basket.Revenue decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ.
ADVERTISEMENT NuvamaWe build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25.
ADVERTISEMENT (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
(You can now subscribe to our ETMarkets WhatsApp channel)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Reliance Retail buys American durables company Kelvinator
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Isha Ambani-led Reliance Retail on Friday announced that the company has acquired American manufacturer Kelvinator to broaden its range of offerings in the fast-growing durables bringing Kelvinator into Reliance's fold, the company said, it aims to combine its massive retail network with Kelvinator's legacy of innovation and trusted which originated in the early 20th century and became a household name in India in the 1970s and '80s with the tagline 'The Coolest One,' retains a nostalgic charm with Indian consumers. Known for its durable and high-performance appliances, the brand has long been associated with reliability, cutting-edge technology, and Industries shares were trading at Rs 1470.40 apiece, down 0.45 per cent on the BSE as of 11.07 AM on Friday."Our mission has always been to serve the diverse needs of every Indian by making technology accessible, meaningful, and future-ready," said Isha M Ambani, Executive Director, Reliance Retail Ventures Limited (RRVL). "The acquisition of Kelvinator marks a pivotal moment, enabling us to significantly broaden our offering of trusted global innovations to Indian consumers. This is powerfully supported by our unmatched scale, comprehensive service capabilities, and market-leading distribution network."Reliance Retail plans to leverage Kelvinator's brand equity and product development legacy to scale up offerings across key consumer durable categories, from refrigerators and washing machines to air conditioners and kitchen Retail said that it is strategically positioned to accelerate category growth, deepen consumer engagement, and unlock substantial long-term opportunities within India's dynamic consumer durables market.
Economic Times
2 hours ago
- Economic Times
Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel "The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel , we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get disentangled," says Sudip Bandyopadhyay , Group Chairman, Inditrade Capital Well, of course, what has changed significantly is the tariff announcement by President Trump. There was a sword hanging on pharma sector and at different levels different figures were being thrown around. But finally, when the announcement came, it talks about very high 200% or whatever but it is after two obviously people immediately started talking about the fact that probably it will never come because if something gets pushed back by two years obviously there is no threat of imminent tariff on pharma products, so that was a fantastic news for most Indian pharma companies because most of them or at least a lot of them have significant business in do manufacture in India and supply to US, so they would have been adversely affected by the tariff and since that is not happening, that was the point from where pharma actually we started seeing significant momentum in largecap and some midcap pharma companies. As far as overall pharma is concerned Sun Pharma does look good because some of the molecules which they were expected to commercialise a bit later in the year is getting preponed and the commercial launch is happening in US very-very soon and that kind of enthused the investors about Sun they have significant business in US as well as India and both the markets are expected to do good. The pricing pressure on generics is, of course, there but that has kind of reached a level where we have seen the course, Glenmark did a landmark deal and it is not only for Glenmark, for the entire Indian pharmaceutical industry this was a landmark deal with R&D getting established and getting properly valued by global pharma players, so this was definitely landmark and of course, Glenmark investors were rewarded and will be rewarded further I am sure in terms of dividend or other some kind of payouts, so that is as far as Glenmark and Sun Pharma is by and large Indian pharma can breathe a sigh of relief post the tariffs sword going away and it is back to business as usual and considering that most of the sectors are kind of still awaiting to know about the tariff and its implications, pharma is one sector where that has been taken care of. Hence, pharma is rallying, that is my it is definitely positive for the overall steel industry. We have to remember that globally also demand for steel is going up and naturally price hike in the domestic scenario is also expected. The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel , we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get is very critical for JSW Steel at this stage. Of course, coking coal prices of the entire industry will be interesting to understands the trend and what the management commentary is for multiple companies not only JSW Steel because that is a very-very critical ingredient as far as steel making is and large, we believe that the industry margins would have improved in this current quarter for which results will come out. Top line depends on company specific like JSW Steel had a scheduled maintenance, so obviously the volume will be low, but the margin improvement will be visible.
Time of India
2 hours ago
- Time of India
Sun Pharma Share Price Live Updates: Sun Pharma's Stock Price Declines Below 100-Day EMA
18 Jul 2025 | 09:35:27 AM IST Discover the Sun Pharma Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing stock. Keep track of Sun Pharma's latest details, including: Last traded price 1697.0, Market capitalization: 407215.13, Volume: 68878, Price-to-earnings ratio 37.26, Earnings per share 45.55. Our liveblog offers a holistic view of Sun Pharma by examining both fundamental and technical indicators. Stay ahead of market trends with breakingnews that can impact Sun Pharma's performance. Our market analysis and expert opinions provide valuable insights to guide your investment decisions. Join us on the Sun Pharma Stock Liveblog and stay informed in this dynamic market landscape. The data points are updated as on 09:35:27 AM IST, 18 Jul 2025 Show more
